Teva: Avoid

Lisensi Anda Salah atau Anda belum memasukkan Lisensi

Source : http://www.fiercepharma.com/pharma/teva-ceo-gets-lots-advice-how-to-fix-beleaguered-company-even-before-he-begins

Teva CEO gets lots of advice on how to fix beleaguered company, even before he begins
Go Long Teva Pharmaceuticals Industries Ltd (ADR) (TEVA) Stock With Less Speculation
New Teva chief must tackle ‘tough decisions’ on jobs
Teva - More Sales, Mind The Proceeds
Teva's Leukemia Drug sNDA Granted Priority Review by the FDA
With $40 Million Pay, Teva Breaks From Custom for Turnaround
Top Analyst Upgrades and Downgrades: ASML, GE, HubSpot, Infosys, Teva, United Continental and Many More
Teva's new CEO faces daunting task in turnaround bid
Teva betting on Schultz as CEO with $40m package
Tribal justice? A clever new patent transfer strategy seeks to avoid Patent Office scrutiny